Your prediction
Pros and Cons of Genetic Technologies Ltd. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
S********** s********
?
C******** o* t** e**********
Cons
?
G***** c******* t* c**********
?
B****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Genetic Technologies Ltd. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Genetic Technologies Ltd. | - | - | - | - | - | - | - |
| Invion Ltd | 0.000% | 0.000% | 5.000% | -47.500% | -47.500% | 2000.000% | 366.667% |
| Immutep LTD ADR | -2.350% | -0.595% | -10.215% | -78.026% | -87.154% | -82.694% | -89.363% |
| Alterity Therapeutics Ltd. ADR | 2.230% | -5.789% | -21.145% | -4.660% | 44.355% | -4.660% | -75.479% |
News
Black Diamond Therapeutics Touts Silevertinib Lung Cancer Data, Eyes FDA Path
Key Points
- Interested in Black Diamond Therapeutics, Inc.? Here are five stocks we like better.
- Silevertinib showed encouraging Phase 2 lung cancer data, including a 60% objective response
Pelthos Therapeutics Q1 Earnings Call Highlights
Pelthos Therapeutics (NYSEAMERICAN:PTHS) reported higher first-quarter revenue as prescriptions for its lead product, ZELSUVMI, continued to grow in the treatment’s third full quarter since launch